Avila Therapeutics, Inc.
http://www.avilatx.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Avila Therapeutics, Inc.
With Serial Entrepreneur At Its Helm, Arrakis Raises $38m To Target RNA With Small Molecules
Serial entrepreneur Michael Gilman has taken the helm of another start-up; after selling Padlock to Bristol-Myers and Stromedix to Biogen, his new company Arrakis has raised a $38m Series A round with big biopharma backing.
Clovis Highlights Pipeline Turnaround Going Into 2014
The small oncology company has recovered from previous setbacks and is now anticipating a strong year to come as it moves two drugs into later-stage development and pivotal trials.
Clovis Highlights Pipeline Turnaround Going Into 2014
The small oncology company has recovered from previous setbacks and is now anticipating a strong year to come as it moves two drugs into later-stage development and pivotal trials.
For Its Latest Epigenetics Deal, Celgene Takes Option To Buy Acetylon
A $100 million, non-dilutive investment will keep Acetylon off the market, giving Celgene the right to buy it for a minimum of $500 million up-front within a pre-determined time window. For now, Acetylon retains all rights to its pipeline, including Phase Ib multiple myeloma drug ACY-1215.
Company Information
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice